Biomedical subjects

S E Pinder

Publications and source records attributed to S E Pinder.

113 records · Page 7Linked to original sources

PubMed1990

Mucins in prostatic carcinoma.

Mucin production by prostatic carcinomas is not unusual and the identification of acidic mucin with an appropriate stain may be a useful adjunct in routine diagnostic surgical pathology. In our series of 53 cases of prostatic carcinoma, 20 (38%) showed significant acidic mucin production. This may allow differentiation from benign, hyperplastic tissues which produce neutral mucins only. A case of colloid carcinoma of prostate is described which satisfies Elbadawi's criteria for this uncommon variant. Some suggestions are made which, if rigorously applied, will permit the recognition of genuine cases of colloid carcinoma and of the prognostic significance of mucin-rich tumours.

Aged↗

PubMedDate not supplied

The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer.

The role of blood tumor markers in monitoring response in advanced breast cancer is established in endocrine therapy and standard chemotherapy. This study examines marker levels in patients receiving new chemotherapy regimens. Thirty patients were recruited into two multicenter trials in which docetaxel-based regimens were used in 15 patients. The other 15 received doxorubicin-based regimens. Biochemical response calculated from a score using CA15.3, CEA and ESR was compared with UICC response. Marker changes at 2, 4 and 5 months correlated with UICC response at 3, 4(1/2) and 6 months, respectively (p < 0.03). Eleven patients achieved both clinical/radiological and biochemical response at the end of treatment; markers had not yet returned to below cutoffs in seven, suggesting a possible advantage to continue chemotherapy. No patient showed a biochemical response whilst judged clinically/radiologically progressive. Nineteen patients had progressed either clinically/radiologically or biochemically at six months; of these, eight showed progression assessed earlier by markers so that a median of four cycles of chemotherapy could have been saved. Measurements of serum c-erbB2 showed a correlation with tissue c-erbB2 staining in the primary tumor (p < 0.003). Among the patients with positive tissue staining, sequential changes in serum c-erbB2 completely paralleled initial response.

Biomarkers, Tumor↗

PubMedDate not supplied

Ductal carcinoma in situ of the human breast: clinico-pathological aspects.

The apparent increase of incidence of DCIS is related to the development of mammographic screening programs and requires an effort of diagnostic, classification and treatment revision. The same natural history of the DCIS is still poorly known, and the phases of its evolution are supposed essentially on epidemiologic and statistics bases. The efforts for a classification are aimed to the search of a prognostic meaning: nuclear grading and possible invasive evolution; association of nuclear grading and necrosis. Both are correlated with local recurrence and free interval. The finding of micro-calcifications is the basis of the instrumental mammographic diagnosis; the possible isolated and unique finding encourages choices of conservative surgery. But as the less large lesions are as a rule of higher grade than those more extended, there are the treatment can be puzzling. As a consequence in fact the former are exposed to wider resections than the last ones. The DCIS is also characterized in its post-surgical evolution from the borders of the excision, from the pathologic classification, from the nuclear degree and from the dimensions of the lesion. In the more favourable conditions the surgical excision represents an adequate treatment. The radiotherapy finds his role in the more elevated degrees and in the case of incomplete excision, also if only presumptive. The alternative is the reoperation and the mastectomy.

Antineoplastic Agents, Hormonal↗

PubMedDate not supplied

The significance of p53 autoantibodies in the serum of patients with breast cancer.

Serum p53 autoantibodies were studied in 82 patients with Stage 1 or 2 breast cancer using an ELISA assay. Tissue expression of p53 in these patients was also examined. High levels of serum p53 autoantibodies were detected in 48% (39/82) patients, while 23% (19/82) were tissue positive. Patients with high serum p53 autoantibodies levels were not significantly different to those with low levels with respect to, tissue p53, tumour grade, size, stage or oestrogen receptor status. Tissue immunoreactivity for p53 was significantly associated with tumour grade and negative oestrogen receptor status. Patients in both groups were followed for a median of over five years but the presence of p53 autoantibodies in serum was not prognostic with respect to disease free interval or survival. In this study detection of p53 autoantibodies in serum does not correlate with any of the usual tumour related prognostic factors, nor does it correlate with clinical outcome.

Antibodies, Neoplasm↗

PubMedDate not supplied

C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer.

BACKGROUND: Previous work suggests that the presence of c-erbB2 oncoprotein immunostaining and the proliferation rate of tumours, may be relevant to chemo-sensitivity in breast cancer. PATIENTS AND METHODS: To investigate this we assessed pretreatment biopsies from 50 patients with locally advanced breast cancer for expression of c-erbB2 and MIB1 (proliferative marker) in relation to clinical response after 3 months preoperative chemotherapy. RESULTS: Objective response was significantly more likely (22/30, 73%) for tumours negative for c-erbB2 membrane staining, compared to positively staining tumours (6/20, 30%, p = 0.0025). The percentage of cells staining positively for MIB1 was not predictive of response (p = 0.56). CONCLUSIONS: This study has shown an increased likelihood of response to preoperative chemotherapy for breast cancers negative for c-erbB2 staining. Previous studies have shown that c-erbB2 immunostaining can correlate with either chemo-resistance or chemo-response. We postulate that this conflict may be due to differences in the type of chemotherapy administered. This raises the possibility of biological markers being use to assist in the selection of the type of chemotherapy regimen administered to particular tumour biological phenotype.

Antigens, Nuclear↗